DC:NOVO-B Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S has a collaboration agreement with Embark Biotech ApS for the discovery of novel treatments for obesity and its associated metabolic pathologies; and e-therapeutics plc to use network-driven drug discovery platform for discovering novel biological mechanisms and therapeutic approaches for a specific area of type-2 diabetes; and Staten Biotechnology B.V. to develop novel therapeutics for the treatment of hypertriglyceridaemia. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.This company has ADRs that trade in the U.S. as the symbol NVO.
1,049.00 EUR
As of 03/24/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Biotechnology
Index country: Denmark
Country of incorporation: Denmark
IPO date: 10/16/2000
Stock exchange: Omx Nordic Exchange Copen
Exchange country: Denmark
Market cap: 1,701,608,685,568 EUR
Current dividend yield: 1.40%
Sedol: BHC8X90